Andrew Fein

H.C. Wainwright Significantly Raises OvaScience Price Target Following Investor Day

In a research report released today, H.C.

Ben Mahaney, Editor — December 18, 2014, 4:53 PM EDT

Seattle Genetics: Continued Quality And Breadth Of Data Should Yield Investor Re-Engagement, Says H.C. Wainwright

H.C.

Corey Williams — December 9, 2014, 1:25 PM EDT

H.C. Wainwright Maintains Buy On Threshold Pharmaceuticals Following TH-302 Phase 1/2 Data

In a research report released Monday, H.C.

Jason Cohen Jason Cohen — December 8, 2014, 4:48 PM EDT

H.C. Wainwright Comments On Vertex Pharmaceuticals As CF Foundation Cashes Out On Kalydeco

In a research report released today, H.C.

Jason Cohen Jason Cohen — November 20, 2014, 3:36 PM EDT

H.C. Wainwright Comments On Neostem Following AMR-001 Data Release

In a research report published Wednesday, H.C.

Ben Mahaney, Editor — November 19, 2014, 2:46 PM EDT

H.C. Wainwright Reaffirms Buy On Synthetic Biologics, Sees 186% Upside

In a research report published today, H.C.

Editor Ben Weinberg — November 18, 2014, 5:30 PM EDT

H.C. Wainwright Reiterates Buy On Threshold Pharmaceuticals, Sees 264% Upside For The Stock

In a research note released yesterday, H.C.

Editor Ben Weinberg — November 13, 2014, 12:02 PM EDT

H.C. Wainwright Reiterates Buy On OvaScience, Increases PT To $40

In a research note published today, H.C.

Editor Ben Weinberg — November 11, 2014, 2:02 PM EDT

H.C. Wainwright Maintains Buy On Catalyst Pharmaceutical Following Presentation At AANEM

In a research report released today, H.C.

Ben Mahaney, Editor — November 11, 2014, 11:12 AM EDT

H.C. Wainwright Reiterates Buy On Insmed, Sees 111% Upside For Stock

In a research note released today, H.C.

Editor Ben Weinberg — November 7, 2014, 7:45 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts